Advances in Therapy
Overview
Advances in Therapy is a peer-reviewed medical journal that publishes cutting-edge research and reviews in various fields of medicine, including pharmacology, clinical practice, and healthcare outcomes. With a focus on innovative therapeutic approaches, this journal provides valuable insights into the latest advancements, helping healthcare professionals enhance patient care and improve treatment outcomes.
Details
Details
Abbr.
Adv Ther
Start
1984
End
Continuing
Frequency
Monthly, 2008-
p-ISSN
0741-238X
e-ISSN
1865-8652
Country
United States
Language
English
Metrics
Metrics
h-index / Ranks: 4133
83
SJR / Ranks: 3284
1089
CiteScore / Ranks: 3723
6.10
JIF / Ranks: 2461
3.8
Recent Articles
1.
Chan J, Ribeiro-Oliveira Jr A, Houchard A, Dennen S, Liu Y, Naga S, et al.
Adv Ther
. 2025 Mar;
PMID: 40080241
Introduction: This study investigated the burden of comorbidities and concomitant non-cancer medications and their cost in patients with neuroendocrine tumors (NETs). Methods: Adults with gastroenteropancreatic (GEP)-NETs and lung-NETs, with or...
2.
Chauchat L, Guerin C, Sahyoun M, Guillon M, Calonge M
Adv Ther
. 2025 Mar;
PMID: 40080240
Introduction: This study aimed to explore the beneficial effect of a preservative-free (PF) emulsion eyedrop combining high molecular weight sodium hyaluronate (HMW-HA) and alpha-lipoic acid on oxidative stress and ocular...
3.
Zhang C, Yu S, Li S, Wu X, Wei Q, He J, et al.
Adv Ther
. 2025 Mar;
PMID: 40080239
Introduction: We aim to evaluate the safety and pharmacokinetic (PK) properties of cefiderocol in Chinese participants, following single and subsequent multiple administrations of 2 g q8h with 3-h intravenous infusion,...
4.
Hu A, Teneralli R, Rodriguez R, Abdul Sultan A, Garey C, Ackert J, et al.
Adv Ther
. 2025 Mar;
PMID: 40080238
Introduction: The increased risk of falls in elderly people represents a substantial public health burden that may be compounded by impaired visual acuity. The present study aimed to assess the...
5.
Moehler M, Oh D, Kato K, Arkenau T, Tabernero J, Lee K, et al.
Adv Ther
. 2025 Mar;
PMID: 40075025
Introduction: Tislelizumab plus investigator-chosen chemotherapy (ICC) demonstrated a statistically significant improvement in overall survival (OS) versus placebo plus ICC in RATIONALE-305 in patients with locally advanced unresectable or metastatic human...
6.
Xu J, Kato K, Hubner R, Park S, Kojima T, Ishihara R, et al.
Adv Ther
. 2025 Mar;
PMID: 40075024
Introduction: The United States Food and Drug Administration Oncologic Drugs Advisory Committee voted (September 2024) against the use of programmed cell death protein-1 inhibitors for first-line treatment of advanced or...
7.
Wang X, Pahwa A, Bausch-Jurken M, Chitkara A, Sharma P, Malmenas M, et al.
Adv Ther
. 2025 Mar;
PMID: 40063213
Introduction: This systematic literature review and pairwise meta-analysis evaluated the comparative effectiveness of mRNA-1273 versus BNT162b2 in patients with at least one underlying medical condition at high risk for severe...
8.
9.
10.
Kaneto H, Hatanaka M, Morimoto Y, Takahashi Y, Terauchi Y
Adv Ther
. 2025 Mar;
PMID: 40056372
Introduction: In this post-marketing study in Japan, the occurrence of hospital-treated hypoglycaemia and severe hyperglycaemia requiring inpatient treatment was evaluated in various cohorts of people with type 2 diabetes (T2D)...